Cinda launches PD-1 adjuvant/neo-adjuvant treatment of NSCLC large-scale international multi-center phase III clinical trial

On November 12, Cinda Bioregistered and initiated a large international multi-center phase III clinical ORIENT-99 study of sintilimab combined with chemotherapy for preoperative neoadjuvant and postoperative adjuvant treatment of non-small cell lung cancer

Last week, immunotherapy has just ushered in the first phase III positive result in the field of neoadjuvant treatment of non-small cell lung cancer: nivolumab achieved EFS (event-free survival) + pCR (pathological complete remission) in the Checkmate-816 study ) Double positive result

ORIENT-99 clinical trial registration

From Insight database (http://db.

ORIENT-99 is the effectiveness and safety of sintilimab combined with chemotherapy or placebo combined with chemotherapy before surgery and sintilimab or placebo after surgery for resectable non-small cell lung cancer.

At present, immunotherapy has gradually captured the front-line to the back-line treatment of major cancers, and adjuvant therapy and neoadjuvant therapy have become a new battlefield for immune checkpoint inhibitors led by PD-1/L1

Clinical registration of domestic PD-1/L1 adjuvant and neoadjuvant therapy

*As of November 9, 2021, only CDE source data is collected